Prolonged remission from hepatic encephalopathy with rifaximin: Results of a placebo crossover analysis

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 39-45

  Bajaj, J S ^a   Barrett, A C ^b   Bortey, E ^b   Paterson, C ^b   Forbes, W P ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ADULT; ARTICLE; ASCITES; CELLULITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEALTH IMPACT ASSESSMENT; HEPATIC ENCEPHALOPATHY; HOSPITAL COST; HUMAN; KIDNEY INFECTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT REPEATABILITY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PERITONITIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; URINARY TRACT INFECTION; AGED; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; INCIDENCE; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA;

AGED; ANTI-INFECTIVE AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RESEARCH DESIGN; RIFAMYCINS;

EID: 84915746507     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12993     Document Type: Article

References (21)

1. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
2. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011; 33: 739-47.
3. Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012; 10: 1034-41.
4. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 1622-6.
5. Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011; 106: 1646-53.
6. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5.
7. Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007; 13: 1366-71.
8. Mullen KD, Ferenci P, Bass NM, Leevy CB, Keefe EB. An algorithm for the management of hepatic encephalopathy. Semin Liver Dis 2007; 27: 32-48.
9. Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med 2010; 362: 1140-2.
10. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005; 62: 2295-304.
11. Bismuth M, Funakoshi N, Cadranel JF, Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol 2011; 23: 8-22.
12. Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis 2012; 16: 301-20.
13. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47.
14. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
15. Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a doubleblind placebo-controlled study. Aliment Pharmacol Ther 2011; 34: 853-61.
16. Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014; 12: 1390-7.e2.
17. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007; 52: 737-41.
18. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-5.
19. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467-84.
20. Ruiz J, Mensa L, Pons MJ, Vila J, Gascon J. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 2008; 61: 1016-9.
21. Fernandez J, Arroyo V. Bacterial infections in cirrhosis: a growing problem with significant implications. Clin Liver Dis 2013; 2: 102-5.